IP Library Granted Patent US 12,310,832
Granted Patent B2
US 12,310,832 · App. 17/551,491 · Granted May 27, 2025

Biliary stents and methods

Inventors: Kenneth F. Binmoeller (San Francisco, CA); Sieu T. Duong (Hayward, CA); Hanh Duong (Hayward, CA); Thao Nguyen (San Jose, CA)
Assignee: Boston Scientific Scimed, Inc.
A61F2/04A61F2/07A61F2/90A61F2002/041A61F2230/001A61F2230/0069A61F2230/0095A61F2250/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,832
App. No.
17/551,491
Granted
May 27, 2025
Kind
B2
Abstract

A tissue lumen stent is provided with a body having an elongated tubular configuration and a foreshortened configuration. In the foreshortened configuration, downstream and upstream ends of the body expand radially into downstream and upstream flange structures, leaving a generally cylindrical saddle region therebetween. In some embodiments, the flange structures are non-symmetrical with respect to one another. Systems and methods of using the stents are also disclosed.

Claims (35)

1. A tissue lumen stent, comprising:

a body having an elongated tubular configuration and a deployed configuration;

wherein, when in the deployed configuration and deployed in tissue, a first end and an opposing second end of the body expand radially into respective first and second flange structures leaving a substantially cylindrical saddle region therebetween;

wherein at least one of the first flange structure and the second flange structure comprises at least first and second points of inflection that define first and second segments of the flange structure, wherein an angle of the first inflection point facing toward a center plane of the cylindrical saddle region and defined by the first segment and the cylindrical saddle region is at least as great as an opposing angle of the second inflection point facing away from the center plane and defined by the first segment and the second segment;

wherein the first segment of the at least one of the first and second flange structures comprises a portion that increases in diameter and the second segment of the at least one of the first and second flange structures comprises a portion that decreases in diameter; and

wherein the first flange structure, the second flange structure, or both, comprise an outwardmost opening having a diameter larger than a maximum diameter of the cylindrical saddle region.

2. The tissue lumen stent of claim 1 , wherein, when the body is deployed in tissue in the deployed configuration, the cylindrical saddle region is measured as the lesser of a length of the body between where the first flange structure joins the body and where the second flange structure joins the body, and a length of the body that is the shortest distance between any point along the first flange structure and any point along the second flange structure.

3. The tissue lumen stent of claim 1 , wherein the at least one of the first and second flange structures comprises the first flange structure, and wherein the first flange structure comprises a larger maximum diameter than a maximum diameter of the second flange structure.

4. The tissue lumen stent of claim 1 , wherein the at least one of the first and second flange structures comprises the first flange structure, and wherein the portion of the first segment of the first flange structure that increases in diameter has a length at least half as long as a maximum diameter of the cylindrical saddle region.

5. The tissue lumen stent of claim 1 , wherein the at least one of the first and second flange structures comprises the first flange structure, and wherein the second flange structure flares outward from the cylindrical saddle region.

6. The tissue lumen stent of claim 1 , wherein the stent comprises an overall length between 10 and 60 mm in the deployed configuration.

7. A tissue lumen stent, comprising:

a body having an elongated tubular configuration and a deployed configuration;

wherein, when in the deployed configuration and deployed in tissue, a first end and an opposing second end of the body expand radially into respective first and second flange structures leaving a substantially cylindrical saddle region therebetween;

wherein at least one of the first flange structure and the second flange structure comprises at least first and second points of inflection that define first and second segments of the flange structure, wherein an angle of the first inflection point facing toward a center plane of the cylindrical saddle region and defined by the first segment and the cylindrical saddle region is at least as great as an opposing angle of the second inflection point facing away from the center plane and defined by the first segment and the second segment;

wherein in the deployed configuration and deployed in tissue a maximum diameter of the cylindrical saddle region is between and inclusive of 5 mm and 20 mm, and a maximum diameter of the at least one of the first and second flange structures is between and inclusive of 20 mm and 40 mm; and

wherein the first flange structure, the second flange structure, or both, comprise an outwardmost opening having a diameter larger than a maximum diameter of the cylindrical saddle region.

8. The tissue lumen stent of claim 7 , wherein, when the body is deployed in tissue in the deployed configuration, the cylindrical saddle region is measured as the lesser of a length of the body between where the first flange structure joins the body and where the second flange structure joins the body, and a length of the body that is the shortest distance between any point along the first flange structure and any point along the second flange structure.

9. The tissue lumen stent of claim 7 , wherein the at least one of the first and second flange structures comprises the first flange structure, and wherein the first flange structure comprises a larger maximum diameter than a maximum diameter of the second flange structure.

10. The tissue lumen stent of claim 7 , wherein, when deployed in tissue, the first segment of the at least one of the first and second flange structures comprises a portion that increases in diameter and the second segment of the at least one of the first and second flange structures comprises a portion that decreases in diameter.

11. The tissue lumen stent of claim 10 , wherein the portion of the first segment of the at least one of the first and second flange structures that increases in diameter has a length at least half as long as the maximum diameter of the cylindrical saddle region.

12. The tissue lumen stent of claim 7 , further comprising a covering or membrane over the cylindrical saddle region, the first flange structure, the second flange structure, or any combination thereof.

13. The tissue lumen stent of claim 7 , wherein the at least one of the first and second flange structures comprises the first flange structure and the second flange structure, and wherein the portions of the first segments of the first and second flange structures that increase in diameter bend back towards each other.

14. A tissue lumen stent, comprising:

a body having an elongated tubular configuration and a deployed configuration;

wherein, when in the deployed configuration and deployed in tissue, a first end and an opposing second end of the body expand radially into respective first and second flange structures leaving a substantially cylindrical saddle region therebetween;

wherein the first flange structure comprises at least first and second points of inflection that define first and second segments of the flange structure, wherein an angle of the first inflection point facing toward a center plane of the cylindrical saddle region and defined by the first segment and the cylindrical saddle region is at least as great as an opposing angle of the second inflection point facing away from the center plane and defined by the first segment and the second segment;

wherein in the elongated tubular configuration the body has a maximum diameter between and inclusive of 0.8 mm and 4.5 mm and in the deployed configuration the at least one of the first and second flange structures has a maximum diameter between and inclusive of 5 mm and 40 mm; and

wherein the first flange structure comprises a larger maximum diameter than a maximum diameter of the second flange structure.

15. The tissue lumen stent of claim 14 , wherein the first flange structure, the second flange structure, or both, comprise an outwardmost opening having a diameter larger than a maximum diameter of the cylindrical saddle region.

16. The tissue lumen stent of claim 15 , wherein, when the body is deployed in tissue in the deployed configuration, the cylindrical saddle region is measured as the lesser of a length of the body between where the first flange structure joins the body and where the second flange structure joins the body, and a length of the body that is the shortest distance between any point along the first flange structure and any point along the second flange structure.

17. The tissue lumen stent of claim 15 , wherein, when deployed in tissue, the first segment of the at least one of the first and second flange structures comprises a portion that increases in diameter and the second segment of the at least one of the first and second flange structures comprises a portion that decreases in diameter.

18. The tissue lumen stent of claim 15 , further comprising a covering or membrane over the cylindrical saddle region, the first flange structure, the second flange structure, or any combination thereof.

19. The tissue lumen stent of claim 15 , wherein in the deployed configuration a maximum diameter of the cylindrical saddle region is between and inclusive of 5 mm and 20 mm, and a maximum diameter of the at least one of the first and second flange structures is between and inclusive of 20 mm and 40 mm.

20. The tissue lumen stent of claim 15 , wherein the portion of the first segment of the at least one of the first and second flange structures that increases in diameter has a length at least half as long as the maximum diameter of the cylindrical saddle region.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2021
From: BINMOELLER, KENNETH F.; DUONG, SIEU T.; DUONG, HANH H.; NGUYEN, THAO
To: XLUMENA, INC.
Reel/Frame 058400/0201 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2021
From: XLUMENA, INC.
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 058400/0324 →
Continuity (5)
Continuation 16825715 · Mar 20, 2020
Continuation 16009619 · Jun 15, 2018
Continuation 14743191 · Jun 18, 2015
Provisional Application 62013908 · Jun 18, 2014
Related Publication 20220104933A1 · Apr 7, 2022
References Cited (75)
US 5425739A · Jessen · 1995 [cited by examiner]
US 5645559A · Hachtman et al. · 1997 [cited by applicant]
US 5893868A · Hanson et al. · 1999 [cited by applicant]
US 7309351B2 · Escamilla et al. · 2007 [cited by applicant]
US 8323350B2 · Nissl · 2012 [cited by examiner]
US 9381041B2 · Brown · 2016 [cited by examiner]
US 9668853B2 · Shin · 2017 [cited by applicant]
US 10278841B2 · Clerc · 2019 [cited by examiner]
US 10327778B2 · Weiner · 2019 [cited by examiner]
US 10722341B2 · Binmoeller · 2020 [cited by examiner]
US 10952732B2 · Binmoeller · 2021 [cited by examiner]
US 20040078071A1 · Escamila et al. · 2004 [cited by applicant]
US 20050055082A1 · Ben Muvhar et al. · 2005 [cited by applicant]
US 20060259113A1 · Nissl · 2006 [cited by examiner]
US 20060276887A1 · Brady · 2006 [cited by examiner]
US 20070016306A1 · Dua et al. · 2007 [cited by applicant]
US 20070179590A1 · Lu · 2007 [cited by examiner]
US 20080228256A1 · Erickson et al. · 2008 [cited by applicant]
US 20090143713A1 · Van Dam et al. · 2009 [cited by applicant]
US 20090157158A1 · Ondracek et al. · 2009 [cited by applicant]
US 20090234429A1 · Lau · 2009 [cited by applicant]
US 20090326431A1 · Heise · 2009 [cited by examiner]
US 20120116496A1 · Chuter et al. · 2012 [cited by applicant]
US 20120130467A1 · Selden et al. · 2012 [cited by applicant]
US 20130274685A1 · Jordan · 2013 [cited by examiner]
US 20130310833A1 · Brown et al. · 2013 [cited by applicant]
US 20130325143A1 · Lamson · 2013 [cited by examiner]
US 20140074065A1 · Muni · 2014 [cited by examiner]
US 20140243950A1 · Weiner · 2014 [cited by examiner]
US 20140257466A1 · Board · 2014 [cited by examiner]
US 20140364959A1 · Attar et al. · 2014 [cited by applicant]
US 20150045908A1 · McMahon · 2015 [cited by examiner]
US 20160081832A1 · Hingston · 2016 [cited by examiner]
US 20160135941A1 · Binmoeller · 2016 [cited by examiner]
US 20160151146A1 · Walak · 2016 [cited by examiner]
US 20160158040A1 · Zupkofska · 2016 [cited by examiner]
US 20160175123A1 · Walsh · 2016 [cited by examiner]
US 20160175125A1 · Brady · 2016 [cited by examiner]
US 20160175126A1 · Walsh · 2016 [cited by examiner]
US 20160242893A1 · Joshi · 2016 [cited by examiner]
US 20160262881A1 · Schankereli · 2016 [cited by examiner]
US 20160345979A1 · Adams et al. · 2016 [cited by applicant]
US 20170086971A1 · Braido et al. · 2017 [cited by applicant]
US 20180185183A1 · Christakis · 2018 [cited by examiner]
US 20180289463A1 · Binmoeller · 2018 [cited by examiner]
US 20190053901A1 · Racchini · 2019 [cited by examiner]
US 20230095107A1 · Brown · 2023 [cited by examiner]
CN 2899736Y · 2007 [cited by applicant]
CN 2910150Y · 2007 [cited by applicant]
CN 201668549U · 2010 [cited by applicant]
CN 201879873U · 2011 [cited by applicant]
CN 203291065U · 2013 [cited by applicant]
CN 103619281A · 2014 [cited by applicant]
CN 103635212A · 2014 [cited by applicant]
CZ 303606B6 · 2013 [cited by applicant]
EP 1795151A1 · 2007 [cited by applicant]
JP 54061393A · 1979 [cited by applicant]
JP S55161539U · 1980 [cited by applicant]
JP H07502673A · 1995 [cited by applicant]
JP 2002233580A · 2002 [cited by applicant]
JP 2003527924A · 2003 [cited by applicant]
JP 2005503881A · 2005 [cited by applicant]
JP 2011156085A · 2011 [cited by applicant]
JP 2016507333A · 2016 [cited by applicant]
JP 20221318A · 2022 [cited by applicant]
KR 20100061506A · 2010 [cited by applicant]
WO 0172239A · 2001 [cited by applicant]
WO 03028522A2 · 2003 [cited by applicant]
WO 2007079153A2 · 2007 [cited by applicant]
WO 2013093112A1 · 2013 [cited by applicant]
WO 2013173045A1 · 2013 [cited by applicant]
Communication pursuant to Article 94(3) for Application No. 15734495.3, dated Mar. 11, 2019, 7 pages. [cited by applicant]
Binmoeller, K.F., et al., “A novel lumen-apposing stent for transluminal drainage of nonadherent extraintestinal fluid collections”, Endoscopy 43:337-342, (2011). [cited by applicant]
Binmoeller et al., “A kit for EUS-Guided Access and Drainage of Pancreatic Psuedocysts: Efficacy in a Porcine Model”, Spring Publishing, vol. 1, Issue 3, 6 pages, Nov. 14, 2012. [cited by applicant]
Binmoeller, et al., “Endoscopic ultrasound-guided gastroenterostomy using novel tools designed for transluminal therapy: a porcine study” Endoscopy 44: © George Thieme Verlag KG Stuttgart—New York, 499-503, 2012. [cited by applicant]